SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AXS is the governance token for the Axie Infinity game. Token holders will be able to shape and vote for the direction of the game universe. This is unlike traditional games where all decisions are made by the game developers. AXS holders will be able to stake their tokens to earn more AXS and even vote for governance proposals.

Axie Infinity

Axie Infinity (AXS) is trending as the community anticipates significant upside potential driven by recent developments, including its integration with Apple Vision Pro, the launch of its V4 engine, and ongoing ecosystem enhancements on the Ronin network. Discussions highlight these strategic advancements and the platform's evolving role within the broader Web3 gaming and AI sectors.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is drawing considerable attention, trending following its pivotal role as the first project on Ethereum's new EIL testnet, which aims to unify L2 chains and enable instant cross-chain automation. The community highlights its innovative "Smart Contracts 2.0" as a core infrastructure play, with growing excitement over recent integrations, increasing holder count, and the impending end of PRQ arbitrage. Many view $REACT as a resilient and severely undervalued asset, primed for significant exposure and adoption in the evolving crypto landscape.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amidst multiple analyst downgrades and intensified concerns over AI competition, including a new creative suite from Apple. The community is sharply divided, with some fearing AI will disrupt Adobe's core business, while others view its strong fundamentals and integrated AI features as a generational buying opportunity during this broader software sector downturn.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is experiencing significant market interest, fueled by ongoing legal developments concerning its co-founder and continued token burn initiatives by major exchanges like Binance. The community is vigorously pushing for a "redemption story," emphasizing ecosystem advancements such as the upcoming LUNCVERSE launch and the passed Terra Classic Forex proposal, alongside intense discussions about supply reduction and its path to long-term revival.

Based Chad

CHAD is experiencing a surge in community conversation, largely fueled by its strong affiliation with Coinbase, including executives actively holding and promoting the token, and Coinbase itself featuring CHAD memes. The community is buzzing about CHAD's unique buyback mechanisms, upcoming video game releases, and its notable resilience during broader market downturns, with many proclaiming "billions is programmed" for this universally recognized meme. Amid discussions of an impending supply shock and potential Base airdrop incentives, CHAD is seen by many as a leading contender for substantial growth within the memecoin ecosystem.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is trending following strong Q4 fiscal year 2025 results that showcased record order intake and a significant backlog, alongside a landmark 1 GW project win in Europe. The market is actively discussing the company's crucial role in powering AI data centers and bolstering grid stability, driving bullish sentiment and positioning it favorably within the growing energy storage sector.

Stratasys Ltd. engages in the development of industrial grade additive solutions. It offers three-dimensional (3D) printer and parts, materials, and software. The company was founded on March 3, 1998 and is headquartered in Eden Prairie, MN.

Stratasys Ltd

Stratasys (SSYS) is currently trending due to a substantial $120 million investment from Fortissimo Capital, signaling confidence in its strategic growth and potential acquisitions. Adding to the buzz, recent congressional insider buying fuels speculation around impending government contracts, aligning with community discussions on additive manufacturing's critical role in defense, medical, and onshoring initiatives, suggesting the stock may be undervalued.

Wishing Well

WISH CRYPTO is gaining significant attention as its community eagerly anticipates key platform updates and chart activation, alongside ongoing contests designed to attract new long-term holders. Discussions highlight its unique deflationary tokenomics on the Solana blockchain, featuring monthly token burns tied to US inflation rates, which proponents believe will reward patient investors and distinguish it from other memecoins.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as its Etherlink L2 recently gained recognition for a "Uranium Tokenization Breakthrough" and staking accessibility expanded across major platforms. The community is actively debating XTZ's potential for Real World Asset (RWA) integration and its role in an anticipated altcoin season, with sentiment sharply divided between bullish predictions and skepticism over its tokenomics and utility. Broader discussions around crypto adoption and market liquidity further contribute to its elevated conversation volume.

Procure ETF Trust II - Procure Space ETF

Procure Space ETF ($UFO) is generating significant buzz as community members highlight its strong performance, touting it as a leading option for broad exposure to the evolving space economy. The ETF benefits from the upward momentum seen in several of its top holdings, alongside growing investor interest evident from new space-focused ETF filings. Discussions emphasize the long-term potential of space investing, moving beyond speculative interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVie Inc. $ABBV Shares Sold by WoodTrust Financial Corp

WoodTrust Financial Corp cut its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 74.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The...

QRG Capital Management Inc. Sells 75,094 Shares of AbbVie Inc. $ABBV

QRG Capital Management Inc. lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 25.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned...

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement...

AbbVie (NYSE:ABBV) Stock Price Down 1.1% - Time to Sell?

AbbVie (NYSE:ABBV) Trading Down 1.1% - Should You Sell...

<ul class="summary-bullets"><li>While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival.&nbsp;</li><li>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma.</li><li>The company said it now intends to engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie.</li></ul> Genmab A/S (GMAB) said on Friday that its late-stage trial evaluating drug Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/16/3220513/0/en/Genmab-Announces-Topline-Results-for-Epcoritamab-DuoBody-CD3xCD20-from-Phase-3-EPCORE-DLBCL-1-Trial-in-Patients-with-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-DLBCL.html">said.</a> While progression-free survival represents the time a patient lives with cancer without it getting worse or dying, overall survival is the length of time from diagnosis or treatment start until death from any cause.<h2 class="st-heading-2">Study Details</h2>Genmab enrolled 483 patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma in the trial who had undergone at least one prior line of therapy. These patients were ineligible for high-dose chemotherapy, the company said.Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma, a blood cancer involving rapid growth of large B-lymphocytes in the lymphatic system, lymph nodes, and other organs, often presenting as fast-growing masses or swollen nodes with symptoms like fever, night sweats, and weight loss. According to Genmab, there are approximately 25,000 new cases of DLBCL diagnosed each year in the U.S.The company said it intends to now engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie. Epcoritamab, being co-developed by Genmab and AbbVie, is already approved in several countries for the treatment of certain lymphomas.Shares of GMAB fell 5% at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GMAB stock stayed within the ‘bearish’ territory coupled with ‘high’ message volume.Meanwhile, sentiment around ABBV shares rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user sees GMAB stock plummet down to $20 from current levels.<stembedurl>https://www.stocktwits.com/nopumpdump/message/642093162</stembedurl><a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> has gained 51% over the past 12 months while <a href="https://stocktwits.com/symbol/ABBV">ABBV shares</a> added 24%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvo-shares-rise-on-strong-kickstart-for-wegoy-pill-in-us/cmUlCCgR4Bq">NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Genmab logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma, the company said.

Equity

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.


AbbVie Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

AbbVie Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) AbbVie Announces...

Pharmaceutical Stocks To Keep An Eye On - January 16th

Eli Lilly and Company, Novo Nordisk A/S, AbbVie, Pfizer, Abbott Laboratories, AstraZeneca, and BridgeBio Pharma are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock...

Zacks Research Comments on AbbVie's Q1 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV - Free Report) - Analysts at Zacks Research boosted their Q1 2026 earnings per share estimates for shares of AbbVie in a research note issued on Wednesday, January 14th. Zacks...

Investors Purchase Large Volume of AbbVie Call Options (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV - Get Free Report) was the target of some unusual options trading on Thursday. Traders purchased 477,943 call options on the stock. This represents an increase of approximately...

AbbVie (ABBV) Stock Dips While Market Gains: Key Facts

AbbVie (ABBV) reached $216.75 at the closing of the latest trading day, reflecting a -2.32% change compared to its last close.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

ABBV
Abbvie Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABBV News

ABBVAbbvie Inc